ABSTRACT
Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the delta variant elicits robust neutralizing antibody response with neutralizing titers an order of magnitude above currently approved mRNA vaccines. The construct also provides protective immunity against the delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern.
ABSTRACT
Botryomycosis is a rare, chronic and suppurative di- sease that is often mistaken clinically and histologically for a fungal infection, because the histologic feature shows a cluster of bacteria found within an eosinophilic matrix or capsule, giving the appearance of granules mimicking the sulfur granules of actinomycosis. Staphy- lococcus aureus is the most common organism cultured from lesions of botryomycosis, but other bacteria have also been isolated and implicated, including Psudomonas aeruginosa, E. coli, Proteus spp., Bacillus spp.. In some case, multiple pathogenic bacteria were found on cul ture. This disease has two patterns of organ involve ment. The more common type is cutaneous type, which involves the skin, subcutaneous soft tissue, muscle and bone. The other is visceral type which involves the lungs, liver, tongue, orbit, bowel, brain, kidney or pros tate. We report a case of brain and pulmonary botry omycosis in a 60 year-old man, who have early lung cancer. Botryomycosis was diagnosed by brain mass removal, PCNA and bronchoscopy, and lung cancer was detected incidentally by bronchoscope. The patient was treated with the Penicillin G after operation of brain mass, and right pneumonectomy was done.
Subject(s)
Humans , Middle Aged , Actinomycosis , Bacillus , Bacteria , Brain , Bronchoscopes , Bronchoscopy , Eosinophils , Kidney , Liver , Lung Neoplasms , Lung , Oceans and Seas , Orbit , Penicillin G , Pneumonectomy , Proliferating Cell Nuclear Antigen , Proteus , Skin , Sulfur , TongueABSTRACT
Reticulum cell sarcoma occurs rarely in central nervous system. It occupies 1-2.5% of all brain tumors. The prognosis is known to be very poor: 3 weeks of mean survival time in case of no treatment, 2 months of mean survival time in case of only surgery, 9 months-3 years of mean survival time in case of both surgery and radiation. We have experienced a case of reticulum cell sarcoma in brain and obtained a good result after surgery and radiation. We report our case with a brief review of the articles.
Subject(s)
Brain , Brain Neoplasms , Central Nervous System , Lymphoma, Non-Hodgkin , Prognosis , Reticulum , Survival RateABSTRACT
Reticulum cell sarcoma occurs rarely in central nervous system. It occupies 1-2.5% of all brain tumors. The prognosis is known to be very poor: 3 weeks of mean survival time in case of no treatment, 2 months of mean survival time in case of only surgery, 9 months-3 years of mean survival time in case of both surgery and radiation. We have experienced a case of reticulum cell sarcoma in brain and obtained a good result after surgery and radiation. We report our case with a brief review of the articles.
